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Background: The role of inflammation and oxidative stress in mild renal impairment in the elderly is not well
studied. Accordingly, we aimed at investigating the associations between estimated glomerular filtration rate
(eGFR), albumin/creatinine ratio (ACR), and markers of different inflammatory pathways and oxidative stress in a
community based cohort of elderly men.
Findings: Cystatin C-based GFR, ACR, and biomarkers of cytokine-mediated inflammation (interleukin-6,
high-sensitivity C-reactive protein[CRP], serum amyloid A[SAA]), cyclooxygenase-mediated inflammation (urinary
prostaglandin F2α [PGF2α]), and oxidative stress (urinary F2 isoprostanes) were assessed in the Uppsala Longitudinal
Study of Adult Men(n = 647, mean age 77 years).
Results: In linear regression models adjusting for age, BMI, smoking, blood pressure, LDL-cholesterol,
HDL-cholesterol, triglycerides, and treatment with statins, ACE-inhibitors, ASA, and anti-inflammatory agents, eGFR
was inversely associated with CRP, interleukin-6, and SAA (β-coefficient −0.13 to −0.19, p < 0.001 for all), and
positively associated with urinary F2-isoprostanes (β-coefficient 0.09, p = 0.02). In line with this, ACR was positively
associated with CRP, interleukin-6, and SAA (β- coefficient 0.09-0.12, p < 0.02 for all), and negatively associated with
urinary F2-isoprostanes (β-coefficient −0.12, p = 0.002). The associations were similar but with lower regression
coefficients in a sub-sample with normal eGFR (>60 ml/min/1.73 m2, n = 514), with the exception that
F2-isoprostane and SAA were no longer associated with eGFR.
Conclusion: Our data indicate that cytokine-mediated inflammation is involved in the early stages of impaired
kidney function in the elderly, but that cyclooxygenase-mediated inflammation does not play a role at this stage.
The unexpected association between higher eGFR/lower albuminuria and increased F2-isoprostanes in urine merits
further studies.
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The increased risk of cardiovascular mortality in patients
with chronic kidney disease (CKD) [1,2] has been attribu-
ted to the clustering of cardiovascular risk factors seen in
these patients [1,3-5]. Untraditional cardiovascular risk
factors such as oxidative stress [6,7] and inflammation* Correspondence: ene@du.se
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reproduction in any medium, provided the or[8] are more prevalent in CKD patients than in normal
individuals [9], and have also been associated with ad-
verse cardiovascular outcomes [5,10-12] and progression
of renal injury in these patients [10]. These observations
suggest that oxidative stress and inflammation may have
an important role in the development of CKD. However,
the role of inflammation and oxidative stress in mild
renal impairment, particularly the role of vasoconstrctive
prostaglandin F2α and F2-isoprostanes, is not well
studied. Moreover, data on the association betweenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Nerpin et al. BMC Research Notes 2012, 5:537 Page 2 of 7
http://www.biomedcentral.com/1756-0500/5/537cytokine mediated inflammation and mild renal impair-
ment in the elderly are scarce.
Cytokines (interleukin-6 [IL-6]), acute-phase proteins
(C-reactive protein [CRP], serum amyloid A protein
[SAA]), and prostaglandins (PGs) are involved in in-
flammatory responses and are used as indicators of sys-
temic inflammation. Prostaglandins of the 2-series are
formed from arachidonic acid by cyclooxygenases at
sites of inflammation, and prostaglandin F2α (PGF2α)—a
major prostaglandin—can be reliably quantified from
the stable PGF2α metabolite (15-keto-dihydro-PGF2α) in
urine [13]. F2-isoprostanes, which are prostaglandin
derivatives, are formed by free-radical-catalysed peroxida-
tion of arachidonic acid. 8-Iso-PGF2α, a major F2-isopros-
tane, is currently regarded as one of the most reliable
indicators of in vivo lipid peroxidation and oxidative stress
[14-16].
Based on previous data, we hypothesised that inflam-
mation and oxidative stress are involved in the early
stages of the development of CKD. Accordingly, we
investigated cross-sectional associations between esti-
mated glomerular filtration rate (eGFR), albuminuria
(albumin/creatinine ratio [ACR]), plasma CRP, IL-6,
and SAA, and urinary PGF2α and F2-isoprostanes in a
community-based sample of elderly men. Moreover, we
studied two pre-specified subgroups with normal eGFR
(> 60 ml/min/1.73 m2) and ACR (< 3 mg/mmol).
Methods
Study sample
The Uppsala Longitudinal Study of Adult Men
(ULSAM) was started in 1970. All fifty-year-old men,
born in 1920–24 and living in Uppsala, Sweden, were
invited to participate in a health survey initially concen-
trating on identification of risk factors for cardiovascular
disease (described in detail at http://www.pubcare.uu.se/
ULSAM/). The present analyses are based on the fourth
examination cycle of the ULSAM cohort, when subjects
were approximately 77 years old (1997–2001, n = 839).
Of these, 647 (77%) had valid measurements of serum
cystatin C, urinary albumin/creatinine ratio, IL-6, CRP,
SAA, urinary PGF2α, F2-isoprostanes, and covariates. All
participants gave written informed consent and the Eth-
ics Committee of Uppsala University approved the study
protocol.
Clinical and biochemical evaluation
Serum cystatin C, high-sensitivity CRP, SAA, and urine
albumin were measured using a BN ProSpec nephelom-
eter (Siemens, Deerfield, IL, USA). The total analytical
imprecision of the cystatin C assay was 4.8% at 0.56 mg/L
and 3.7% at 2.85 mg/L High-sensitivity IL-6 was analysed
with an ELISA kit (IL-6 HS; R&D Systems, Minneapolis,
MN, USA). eGFR was calculated from serumcystatin C results in mL/min/1.73 m2 by the formula
y = 77.24x-1.2623, which have been shown to be closely cor-
related with iohexol clearance [17].
Urine creatinine was analysed by a modified kinetic
Jaffe reaction on an Architect Ci8200W analyser (Abbott,
Abbot Park, IL, USA) and reported in mmol/L;
creatinine-related urine albumin was calculated from the
ProspecW results. Urinary samples were analysed for
15-keto-dihydro-PGF2α , a stable metabolite of PGF2α,
with a radioimmunoassay that has been described previ-
ously in detail [18]. Urinary 15-keto-dihydro-PGF2α con-
centrations were divided by urinary creatinine levels.
Urinary F2-isoprostanes (free 8-iso-PGF2α without any
prior extraction or purification) were analysed with a
radioimmunoassay that has been described previously
[19]. Urinary 8-iso-PGF2α concentrations were divided
by urinary creatinine levels.
Plasma glucose, serum lipids, blood pressure, and body
mass index (BMI) were assessed as previously described
[20]. Diabetes mellitus was diagnosed as a fasting plasma
glucose level of ≥ 7.0 mmol/l (≥ 126 mg/dl), or by the
use of oral hypoglycaemic agents or insulin. Smoking
status (current smoker or non-smoker) and information
concerning pharmacological treatment was recorded
using a questionnaire. Information about hospitalisation
because of myocardial infarction, angina pectoris, ischae-
mic stroke, and heart failure was obtained from the
Swedish hospital discharge register.
Statistical analysis
Logarithmic transformation was performed to obtain a
normal distribution of urine albumin/creatinine ratio,
CRP, PGF2α, IL-6, SAA, F2-isoprostanes, glucose, and tri-
glycerides. All other variables were normally distributed.
Linear regression analyses were used to assess the cross-
sectional associations between CRP, PGF2α, IL-6, SAA,
and F2-isoprostanes (independent variables) and eGFR
and albumin/creatinine ratio (dependent variables in
separate models). We used the directed acyclic graphs
(DAG) approach to establish a parsimonious model with
minimised confounding of the effect estimates in the
statistical model B.
The following models were performed:
– Model A: age-adjusted (continuous);
– Model B: age (continuous), BMI (continuous),
smoking (binary), systolic and diastolic blood
pressure (continuous), LDL-cholesterol, HDL-
cholesterol, and triglycerides (continuous), statin
treatment (binary), ACE inhibitors, ASA, and anti-
inflammatory agents including cortisone (binary).
We also performed the above analyses in a subgroup ana-
lysis between CRP, PGF2α, IL-6, SAA, and F2-isoprostanes
Table 1 Characteristics of the whole study population
Variable Whole sample (n = 647)
Age (years) 77.5 ± 0.8
Urine albumin creatinine ratio (mg/mmol) 4.6 ± 19.4
Serum cystatin C (mg/L) 1.09 ± 0.28
eGFR* (ml/min/1.73 m2) 73.6 ± 17.4
Fasting plasma glucose (mmol/L) 5.9 ± 1.3
Systolic blood pressure (mmHg) 150.9 ± 20.7
Diastolic blood pressure (mmHg) 81.3 ± 9.7
Body mass index (kg/m2) 26.3 ± 3.5
Serum triglyceride (mmol/L) 1.4 ± 0.6
HDL cholesterol (mmol/L) 1.3 ± 0.3
LDL cholesterol (mmol/L) 3.5 ± 0.9
Urine 15-keto-dihydro-PGF2α (nmol/mmol) 0.32 ± 0.18
Serum interleukin-6 (ng/L) 3.9 ± 2.7
Serum amyloid A protein (mg/L) 11.3 ± 43.6
high sensitivity C-reactive protein (mg/L) 3.8 ± 6.8
Urine F2-isoprostane (nmol/mmol) 0.20 ± 0.10
Diabetes mellitus – n (%) 91 (14.1)
Smoking – n (%) 45 (7.0)
Dyslipidemia – n (%) 226 (34.9)
Lipid lowering treatment – n (%) 119 (18.4)
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with eGFR>60 ml/min/1.73 m2 (n=514), and (2) partici-
pants with ACR<3 mg/mmol (n=522).
Moreover, we performed analyses in participants with-
out anti-inflammatory agents (n = 612). We also per-
formed a secondary multivariable model where diabetes
and cardiovascular disease where added to multivariable
model B (model C). The reason that diabetes and cardio-
vascular disease was not included in our primary models
was that these factors may be considered to be in the
causal pathway between inflammation and renal damage.
Moreover, we investigated the association between eGFR
and F2-isoprostanes after excluding participants with
diabetes (n = 83) and individuals with the highest eGFR
(upper decile, > 95 ml/min/1.73 m2, n = 63) to rule out
the risk of glomerular hyperfiltration as an explanation
of our findings.
In our primary analysis, we modelled CRP, PGF2α,
IL-6, SAA, F2-isoprostanes, eGFR, and albumin/creatinine
ratio as continuous variables (expressed as a 1-standard
deviation increase).
A two-sided p-value of < 0.05 was regarded as sig-
nificant in all analyses. The statistical software package
STATA 11.0 was used (Stata Corp., College Station,
TX, USA).Cardiovascular disease – n (%) 175 (27.1)
Hypertension – n (%) 292 (45.1)
Antihypertensive treatment – n (%) 272 (42.0)
Findings
Table 1 shows the characteristics of the study population.ACE-inhibitor – n (%) 109 (16.9)
ASA medicine – n (%) 193 (29.8)
Corticosteroid treatment – n (%) 26 (4.0)
Non-steroidal anti-inflammatory drugs – n (%) 35 (5.4)
Data are mean ± SD for continuous variables and n. (%) for dichotomous
variables. *eGFR was estimated from cystatin C.Associations between inflammatory biomarkers, cystatin
C-based glomerular filtration rate (eGFR), and albumin/
creatinine ratio levels (ACR)
In the whole cohort, eGFR was inversely associated and
ACR was positively associated with CRP, IL-6, SAA,
when adjusting for age, BMI, smoking, systolic and
diastolic blood pressure, hypertension treatment, LDL-
cholesterol, HDL-cholesterol, triglycerides, treatment
with statin, ACE inhibitors, ASA, anti-inflammatory
agents, diabetes, and previous cardiovascular disease
(models A–C, Table 2).
After further exclusion of participants with impaired
eGFR (< 60 ml/min/1.73 m2) the association between
eGFR, CRP, and IL-6, remained statistically significant in
all models but with lower regression coefficients. No sig-
nificant association was seen between eGFR and urinary
PGF2α in the whole cohort or in participants with
eGFR > 60 ml/min/1.73 m2. After exclusion of partici-
pants with ACR> 3 mg/mmol, ACR was found to be
positively associated with PGF2α metabolite and SAA
adjusted for age (Table 2), while no significant associ-
ation was seen in models B and C between ACR and the
inflammatory markers. The results were unaltered in asub-sample of participants without anti-inflammatory
agents (data not shown).Association between oxidative stress, glomerular filtration
rate, and albumin/creatinine ratio levels
In the whole cohort, eGFR was positively associated and
ACR was inversely associated with urinary F2-isoprostanes
in all multivariable models (models A–C, Table 3). After
further exclusion of participants with impaired eGFR
(< 60 ml/min/1.73 m2) and ACR> 3 mg/mmol separately,
no associations were found between levels of the two
kidney markers and urinary F2-isoprostanes.
The association between eGFR and F2-isoprostanes
was essentially similar after excluding participants with
diabetes and eGFR > 95 ml/min/1.73 m2 (model B,
β-coefficient 0.08 [95% CI 0.005–0.15]; p = 0.04).
Table 2 Cross-sectional associations between high sensitive C-Reactive Protein (CRP), Interleukin 6 (IL- 6),
Prostaglandin F2 alpha (PGF2alpha), serum amyloid protein (SAA) and eGFRcyst and albumin creatinine ratio (ACR) at
age 77: Multivariable regression
Cystatin C estimated glomerular filtration rate lnAlbumin creatinine ratio (ACR)
total cohort (n = 647) eGFR> 60 ml/min/1.73 m2 (n= 514) total cohort (n = 647) ACR<3 mg/mmol (n = 522)
β-coefficient (95% CI) β-coefficient (95% CI) β-coefficient (95% CI) β-coefficient (95% CI)
Model A
ln CRP (mg/L) −0.23 (−0.30 to −0.15)*** −0.10 (−0.17 to −0.34)** 0.11 (0.03 to 0.19) ** 0.07 (−0.04 to 0.06)
ln PGF2α (nmol/mmol) −0.01 (−0.07 to 0.08) −0.01(−0.08 to −0.05) 0.01 (−0.07 to 0.09) 0.05 (0.002 to 0.10) *
ln IL-6 (ng/L) −0.28 (−0.35 to −0.20)*** −0.10 (−0.17 to −0.04) ** 0.13 (0.06 to 0.21) ** 0.01 (−0.04 to 0.05)
ln SAA (mg/L) −0.15 (−0.22 to-0.07)*** −0.05 (−0.12 to 0.02) 0.14 (0.06 to 0.21) ** 0.05 (0.002 to 0.10) *
Model B (DAG adjusted)
ln CRP (mg/L) −0.19 (−0.26 to −0.11)*** −0.09 (−0.16 to −0.02) ** 0.09 (0.01 to 0.16) * −0.01 (−0.05 to 0.04)
ln PGF2α (nmol/mmol) −0.01 (−0.07 to 0.08) −0.02 (−0.09 to 0.04) 0.01 (−0.06 to 0.09) 0.03 (−0.01 to 0.08)
ln IL-6 (ng/L) −0.23 (−0.30 to −0.15) *** −0.09 (−0.16 to −0.02)* 0.11 (0.03 to 0.19) ** −0.01 (−0.05 to 0.04)
ln SAA (mg/L) −0.13 (−0.21 to −0.06)** −0.05 (−0.12 to 0.02) 0.12 (0.05 to 0.20) ** 0.04 (−0.008 to 0.09)
Model C
ln CRP (mg/L) −0.19 (−0.26 to −0.11)*** −0.09 (−0.16 to −0.02)** 0.08 (0.01 to 0.16) * −0.01 (−0.06 to 0.04)
ln PGF2α (nmol/mmol) −0.01 (−0.07 to 0.08) −0.02 (−0.09 to 0.04) −0.04 (−0.08 to 0.07) 0.03 (−0.02 to 0.08)
ln IL-6 (ng/L) −0.23 (−0.30 to −0.15)*** −0.09 (−0.16 to −0.02)** 0.09 (0.01 to 0.16) * −0.01 (−0.06 to 0.04)
ln SAA (mg/L) −0.13 (−0.21 to −0.06)*** −0.05 (−0.12 to 0.02) 0.11 (0.04 to 0.19) ** 0.04 (−0.01 to 0.09)
Data are regression coefficients for a 1-SD higher ln C-reactive protein (CRP), ln interleukin 6 (IL- 6), ln prostaglandin F2 ln α (PGF2α),ln serum amyloid protein A
(SAA). Model A was adjusted for age; model B was adjusted according to directed acyclic graphs (DAG): age, BMI, smoking, systolic and diastolic blood pressure,
LDL, HDL, and triglyceride, statin treatment, ACE inhibitor-, ASA-, anti-inflammation-, and cortisone medication. Model C was adjusted for: age, BMI, smoking,
systolic and diastolic blood pressure, hypertension treatment, LDL, HDL, and triglyceride, statin treatment, diabetes, ACE inhibitor-, ASA-, anti-inflammation-, and
corticosteroid treatment, and CVD. * p < 0.05, **p < 0.01. *** p < 0.001.
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Principal findings
In this community-based sample of elderly men, reduced
eGFR and increased ACR were associated with higher
systemic CRP, IL-6, and SAA concentrations. The associ-
ation between eGFR, CRP, and IL-6 remained significant
in participants without any apparent signs of kidney dys-
function (eGFR > 60 ml/min/1.73 m2).Table 3 Cross-sectional associations between oxidative stress
creatinine ratio (ACR) at age 77: Multivariable regression





β-coefficient (95% CI) β-coefficie
Model A
ln F2-isoprostane (nmol/mmol) 0.08 (0.006 to 0.16)* 0.04 (−0.
Model B (DAG adjusted)
ln F2-isoprostane (nmol/mmol) 0.09 (0.02 to 0.17)* 0.03 (−0.
Model C
ln F2-isoprostane (nmol/mmol) 0.09 (0.01 to 0.16)* 0.03 (−0.
Data are regression coefficients for a 1-SD urinary ln F2-isoprostanes. Model A was
(DAG): age, BMI, smoking, systolic and diastolic blood pressure, LDL, HDL, and trigly
medication. Model C was adjusted for: age, BMI, smoking, systolic and diastolic bloo
treatment, diabetes, ACE inhibitor-, ASA-, anti-inflammation-, and corticosteroid treaOur findings are in accordance with most, but not
all [21], previous community-based studies that found
independent associations between biomarkers of cyto-
kine-mediated inflammation (C-reactive protein, tumor
necrosis factor alpha, interleukin-6, and fibrinogen)
and eGFR, measured with serum creatinine [22-25],
cystatin C [8,26], and albuminuria [25,27,28]. We are
aware of one previous study that have reported these(urinary F2-Isoprostanes) and eGFRcyst and albumin







nt (95% CI) β-coefficient (95% CI) β-coefficient (95% CI)
03 to 0.11) −0.13 (−0.20 to −0.05) *** 0.004 (−0.04 to 0.05)
03 to 0.10) −0.12 (−0.19 to −0.04) ** 0.0008 (−0.05 to 0.05)
04 to 0.10) −0.12 (−0.20 to −0.05) *** −0.001 (−0.05 to 0.05)
adjusted for age; model B was adjusted according to directed acyclic graphs
ceride, statin treatment, ACE inhibitor-, ASA-, anti-inflammation-, and cortisone
d pressure, hypertension treatment, LDL, HDL, and triglyceride, statin
tment, and CVD. * p < 0.05, **p < 0.01. *** p < 0.001.
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signs of kidney damage or dysfunction [8]. Systemic
inflammation has been considered to be a risk factor
for CKD, but may also represent a common pathway
by which cardiovascular risk factors interact to amplify
renal injury [9,29].
To our knowledge, this is the first study to have inves-
tigated the association between markers of kidney dam-
age and dysfunction and in vivo PGF2α concentrations.
However, no independent associations were seen be-
tween these markers of kidney pathology and urinary
PGF2α metabolite in this study, indicating that
cyclooxygenase-mediated inflammation is not involved
in the early stages of chronic kidney disease.
Surprisingly, increased eGFR and reduced ACR were
associated with higher levels of urinary F2-isoprostanes
in the whole cohort. Since oxidative stress is suggested
to play an important role in the development of kidney
disease, based on experimental studies [30,31], this find-
ing was contradictory to what we originally hypothe-
sised. Yet, a similar finding was seen in a recent study
from the Framingham Offspring Study, where indivi-
duals with CKD had lower urinary isoprostanes than
individuals without CKD [25]. In contrast, a study on
obese children [32] failed to show any linear correlation
between plasma cystatin C, albuminuria, and urinary
F2-isoprostanes.
The unexpected associations found between kidney
biomarkers and intact urinary F2-isoprostanes in the
present study may possibly be related to the fact that F2-
isoprostanes were quantified in urine but not in plasma
[33]. Studies have shown that patients with manifested
moderate to severe chronic kidney disease [9] and dialy-
sis patients [6,7,29,34] have higher plasma concentrations
of F2-isoprostane than healthy subjects. Furthermore, an
inverse correlation was shown between eGFR and plasma
F2-isoprostanes in hypertensive patients [29]. The kidney
is one of the major sites of both 15-prostaglandin de-
hydrogenase (15-PGDH) and Δ13-reductase, the two
major enzymes that metabolise prostaglandins and F2-
isoprostanes to 15-keto-dihydro-metabolites for further
degradation to more polar β- and ω-oxidised products in
the liver before excretion together with unmetabolised
primary PGF2α and F2-isoprostanes [35,36]. Perhaps the
discrepancy in plasma and urine may be explained by
the possibility that impairment of these enzymes in the
kidney affects both the metabolism and further excretion
of intact F2-isoprostanes into the urine, although to
our knowledge this has not been reported. The fact that
the positive association between eGFR and urinary F2-
isoprostanes was essentially similar after excluding parti-
cipants with diabetes and individuals with the highest
eGFR indicates that glomerular hyperfiltration does not
explain the unexpected findings.The strengths of our investigation include the
homogenous, community-based study sample with
detailed characterisation of glucometabolic variables, car-
diovascular risk factors, and lifestyle factors. Some limita-
tions of our study must also be discussed. As we only
examined men of the same age and of similar ethnic
background, the degree of generalizability to women or
to other ages and ethnic groups is unknown. Further-
more, we did not use the gold standard method to meas-
ure GFR (clearance measurements with exogenous
substances), as this method is generally not feasible in
large study samples. Also, our cystatin C assay was not
calibrated to the new international reference standard
[37,38]. Moreover, as no data on serum creatinine was
available, we were unable to use the recently proposed
GFR equation that incorporates both calibrated cystatin
C and creatinine [39]. However, the cystatin C-based
GFR equation used in the present study [17] has been
shown to be closely associated with GFR measured with
iohexol clearance also in individuals with GFR in the nor-
mal range. This study was also limited by the use of a sin-
gle urine collection for assessment of ACR. Yet, any
potential bias from variations in ACR and GFR levels
would most likely conservatively bias our regression esti-
mates. Moreover, no conclusions regarding causality
should be drawn from our cross-sectional observational
data. Finally, we cannot rule out that participants with
unidentified inflammatory disease may have influenced
the associations, but as this is a healthy community
based-sample, this potential bias is not likely to be major.
Conclusions
Our data indicate that cytokine-mediated inflammation
is involved already in the early stages of impaired kidney
function in the elderly, but that cyclooxygenase-mediated
inflammation does not appear to play a role at this stage.
Whether anti-inflammatory therapies are effective in
slowing down the deterioration of kidney function in the
elderly remain to be established. In order to clarify the
relevance and the underlying pathophysiology of the unex-
pected association between higher urinary F2-isoprostane
concentrations and higher eGFR/lower albuminuria, fur-
ther experimental studies are needed.
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